Drug intelligence / Profile preview

YDC103

Development stage: Preclinical
Lead developer: YD Global Life Science
Modality: Small Molecules

Overview

YDC103 is an experimental drug candidate currently in the lead optimization stage of preclinical development for the treatment of Alzheimer's disease. Developed by YD Global Life Science in collaboration with SapiensBio, YDC103 is designed as a dual-target therapy that addresses both amyloid-beta (Aβ) and tau protein pathologies. This multi-target approach aims to interfere with the aggregation and accumulation of these proteins, which are central to the neurodegenerative process in Alzheimer's. The drug is being developed using SapiensBio's AI-driven discovery platform, which focuses on identifying small molecule candidates with optimized binding profiles for complex biological targets.

Targets

MAPT (Microtubule-associated protein tau)Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on YDC103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YDC103.

Explore the full profile